|
Post by mnholdem on Sept 26, 2018 4:31:10 GMT -5
|
|
|
Post by mnholdem on Sept 25, 2018 21:50:01 GMT -5
Stop picking on the technicians. ;-)
|
|
|
Post by mnholdem on Sept 25, 2018 8:41:55 GMT -5
To add to the above comments, the pump works continuously for 48 hrs and is then replaced. They didn't mention if they were recycled by the factory or you just throw it out. Sounds expensive/wasteful. The drug volume is pretty small. My guess is 10cc/day. Apparently all batteries expand when they are being discharged and the pump uses the swelling of the battery to force the drug out of a small bladder. Seems like a novel and clever way to accurately dispense small volumes. I think the reason the other treatments use an IV or a pump because the drug needs to be continuously put into the patient. I might be wrong about this. The big unknown to me is how TrepT can deliver a constant and continuous supply of the drug. The trial used healthy patients so this wouldn't really be an issue for the trial. I don't think Mike mentioned anything about this. I'm sure there is a good answer, I just don't know what it is. Treprostinil isn’t delivered continuously. Patients take multiple inhalations several times a day.
|
|
|
Post by mnholdem on Sept 24, 2018 14:39:46 GMT -5
Sorry there was no shout box but liane was unavailable and I was participating in a conference call at work while Mike C was presenting.
|
|
|
Post by mnholdem on Sept 24, 2018 8:18:23 GMT -5
The first cohort studied Afrezza in children aged 13-17;
The second cohort will study Afrezza in children aged 8-12 years
The third cohort will study children aged 4-7 years.
At least I think so. The original information was that the FDA wanted children as young as 4 years to be included in the trial.
|
|
|
Post by mnholdem on Sept 24, 2018 7:56:44 GMT -5
And if a company wants to rid themselves of a bad employee they will give a glowing reference to the hiring company..... At least thats how it works at my factory! If your HR Department gives that "glowing review" you could possibly be sued by the employer who hired the guy based on your recommendation. Convention wisdom today among HR journals is to not provide performance information about a current/former employee.
|
|
|
Post by mnholdem on Sept 24, 2018 6:35:34 GMT -5
On ProBoards, PM mean Private Message.
|
|
|
Post by mnholdem on Sept 23, 2018 19:58:50 GMT -5
Nassi was loathed back when he worked for Sanofi. Who the hell does Castagna have doing the hiring at corporate! Don’t they look at more than a resume?
Stuart Tross right? A PhD in organizational psychology doesn’t always translate to practical experience apparently. (I apologize in the event the hiring of Tross was after the hiring of Stassi).
Building a motivated sales force is not an easy task. Lots of complacency to sift through. Big plus if the interviewers are experienced at spotting phonies, though, and contact those references. I miss the good old days when your could call a former employer and get a straight answer. Nowadays HR will only confirm employment start and end dates.
|
|
|
Post by mnholdem on Sept 23, 2018 16:15:52 GMT -5
The marketing activity in these countries is to hospitals and physicians (aka education) and $ to influence them is certainly involved. That’s why it’s crucial to have a regional partner who already has the resources and relationships in place. In Brazil, Biomm has been around for a long time.
|
|
|
Post by mnholdem on Sept 23, 2018 11:44:13 GMT -5
To Readers: Several ProBoards members have asked where I discovered evidence that early insulin treatment restores beta cell output of insulin and reduces insulin resistance. This is one of many published articles on the subject. INTRODUCTION OF INSULIN EARLIER IN THE TREATMENT PARADIGM Typically, whereas introducing insulin therapy in a more timely fashion would significantly improve glycemic control among subjects with type 2 diabetes, the question of insulin initiation timing in relation to other antiglycemic therapies is the subject of considerable debate (10). While insulin administration has the potential of achieving the most effective reductions in glycemic control, the initiation of insulin therapy requires greater use of resources, time, and effort from provider and patient alike, compared with oral antidiabetic therapies (11). Patient resistance to the use of insulin therapy remains a challenge, especially in populations that may have misgivings and misconceptions regarding the role of insulin replacement in diabetes management. Notwithstanding these issues, there are specific populations that would clearly benefit from early, aggressive, and targeted introduction of insulin therapy. For instance, patients presenting with significant hyperglycemia may benefit from timely initiation of insulin therapy that can effectively and rapidly correct their metabolic imbalance and reverse the deleterious effects of excessive glucose (glucotoxicity) and lipid (lipotoxicity) exposure on β-cell function and insulin action (12). In vitro studies have demonstrated that chronic hyperglycemia leads to increased production of reactive oxygen species, and subsequent oxidative stress, which appears to affect insulin promoter activity (PDX-1 and MafA binding) and results in diminished insulin gene expression in glucotoxic β-cells (13). Interestingly, in vitro experiments have shown that these glucotoxic effects occur in a continuum of glucose concentrations (no clear threshold effect), are reversible with reinstitution of euglycemic conditions, and result in the greatest recovery of β-cell function with shorter periods of exposure to hyperglycemia (14). Various studies have demonstrated improvement in insulin sensitivity and β-cell function after correction of hyperglycemia with intensive insulin therapy (15). Source: www.ncbi.nlm.nih.gov/pmc/articles/PMC2811460/
|
|
|
Post by mnholdem on Sept 21, 2018 17:17:41 GMT -5
“Buy the dip and sell the rip”.
|
|
|
Post by mnholdem on Sept 21, 2018 15:07:57 GMT -5
Dark pools reporting in. Fund rebalancing. All sorts of fun stuff.
|
|
|
Post by mnholdem on Sept 21, 2018 14:53:39 GMT -5
Triple witching hour.
|
|
|
Post by mnholdem on Sept 20, 2018 18:29:52 GMT -5
Congratultions brentie! I’ll buy you a ProBoards-MNKD badge just as soon as I see a return on my investment. (Psst...I think you’ll get it before EOY.)
|
|
|
Post by mnholdem on Sept 20, 2018 17:26:14 GMT -5
It’s on Monday.
|
|